Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | APAF1 | O14727 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.45 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13334112 | 0.99 | HDAC1 (0.50) | HDAC1HDAC4LMNAAPAF1ALDH1A1 | |
| Bromide SCHEMBL9528497 | 0.93 | LMNA (0.52) | HDAC1HDAC4LMNAAPAF1ALDH1A1 | |
| SCHEMBL13361702 | 0.92 | GGPS1 (0.46) | HDAC1HDAC4LMNAAPAF1ALDH1A1 | |
| SCHEMBL4401284 | 0.91 | HDAC1 (0.56) | HDAC1HDAC4CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL21629848 | 0.85 | GGPS1 (0.47) | HDAC1HDAC4LMNAAPAF1ALDH1A1 | |
| SCHEMBL5290862 | 0.85 | HDAC1 (0.55) | HDAC1HDAC4LMNAAPAF1ALDH1A1 | |
| SCHEMBL5303900 | 0.85 | HDAC1 (0.59) | HDAC1HDAC4LMNAAPAF1ALDH1A1 | |
| Water SCHEMBL30259465 | 0.85 | HDAC1 (0.55) | HDAC1HDAC4LMNAAPAF1ALDH1A1 | |
| SCHEMBL21629876 | 0.85 | HDAC1 (0.59) | HDAC1HDAC4CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL29724061 | 0.85 | HDAC1 (0.59) | HDAC1HDAC4CHRNA7CHRNA10CHRNA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | claimed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | claimed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | claimed |
| WO-2007149392-A1 | MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY (US) | 2007-12-27 | — | — | WO | claimed |
| US-9550753-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | disclosed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2007149392-A1 | MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | HDAC1 204/4885HDAC4 489/4885LMNA 4419/4885 |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | HDAC1 209/4885HDAC4 503/4885LMNA 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.